The investment bank said that the company's noninvasive genomic test for melanoma detection could capture a large market currently served by invasive biopsies.
The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.
The skin cancer diagnostics company said it delivered 19 percent fewer DecisionDx-Melanoma test results in Q2 2020 than in the previous year's second quarter.
Researchers have developed a method, called MemorySeq, to identify genes transcriptome-wide whose expression fluctuations persist for several cell divisions.
Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.
Along with significantly mutated genes across cutaneous melanoma cases, researchers saw loss-of-function mutations in the X chromosome gene DDX3X in tumors from male patients.
In PNAS this week: genetic variants linked to a pediatric periodic fever syndrome, TERT promoter mutations influencing BRAF and MEK inhibitor response, and more.
Microbiotica, Cambridge University, and Cancer Research UK will develop microbiome co-therapeutics and gut bacteria signatures for predicting immunotherapy response.
A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
